Determination of the effect of calcineurin inhibitors on the rat's immune system after KLH immunisation

Toxicology Letters

Volumn 149, Issue 1-3, 2004, Pages 133-140

  Roman, D ^a,b   Ulrich, P ^a   Paul, G ^a   Court, M ^a   Vit, P ^a   Kehren, J ^a   Mahl, A ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Novartis Pharma AG   (Switzerland)

Author keywords

Cyclosporin A; Flow cytometry; Immune response; KLH; Pimecrolimus; Tacrolimus

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; KEYHOLE LIMPET HEMOCYANIN; PIMECROLIMUS; TACROLIMUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; CELL COUNT; CELL INFILTRATION; CELL SUBPOPULATION; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; IMMUNE DEFICIENCY; IMMUNE FUNCTION TEST; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN PRODUCTION; IMMUNOPHENOTYPING; LEUKOCYTE; LYMPH NODE; LYMPHOCYTE; LYMPHOID TISSUE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, SURFACE; B-LYMPHOCYTES; CALCINEURIN; CYCLOSPORINE; HEMOCYANIN; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOGLOBULIN G; LEUKOCYTE COUNT; LYMPH NODES; LYMPHOCYTES; MALE; PHENOTYPE; RATS; RATS, WISTAR; SPLEEN; T-LYMPHOCYTES; TACROLIMUS;

ANIMALIA;

EID: 1842817485     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2003.12.027     Document Type: Conference Paper

References (16)

1. Bornhovd E., Burgdorf W.H., Wollenberg A. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J. Am. Acad. Dermatol. 45:2001;736-743.
2. Burchiel S.W., Kerkvliet N.L., Gerberick G.F., Lawrence D.A., Ladics G.S. Assessment of immunotoxicity by multiparameter flow cytometry. Fundam. Appl. Toxicol. 38:1997;38-54.
3. European Agency for the Evaluation of Medicinal Products, London, UK, 2000. Note for Guidance on Repeated Dose Toxicity. Committee for proprietary medicinal products (CPMP/SWP/1042/99).
4. Eichenfield L.F., Beck L. Elidel (pimecrolimus) cream 1%: a nonsteroidal topical agent for the treatment of atopic dermatitis. J. Allergy Clin. Immunol. 111:2003;1153-1168.
5. Glantz, S.A., 1992. Primer of Biostatistics, third ed. Mc Graw-Hill, New York.
6. Henry M.L. Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. Clin. Transplant. 13(3):1999;209-220.
7. ILSI Health and Environmental Sciences Institute (HESI), 1999. Application of Flow Cytometry to Immunotoxicology Testing. Immunotoxicity Technical Committee: Report from an October 1997 Workshop. ILSI HESI, Washington, DC.
8. Irwin M. Brain corticotropin-releasing hormone- and interleukin-1 beta-induced suppression of specific antibody production. Endocrinology. 133:1993;1352-1360.
9. Laube G.F., Berger C., Goetschel P., Leumann E., Neuhaus T.J. Immunization in children with chronic renal failure. Pediatr. Nephrol. 17:2002;638-642.
10. Leung D.Y., Boguniewicz M. Advances in allergic skin diseases. J. Allergy Clin. Immunol. 111:2003;S805-S812.
11. Meingassner J.G., Grassberger M., Fahrngruber H., Moore H.D., Schuurman H., Stutz A. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br. J. Dermatol. 137:1997;568-576.
12. Ohtsuki M., Nakagawa H., Sugai J., Ozawa A., Ohkido M., Nakayama J., Hanada J., Morimoto Y., Jimbow K., Horikoshi T., Kitahara H., Tamaki K., Urabe K., Hori Y. Long-term continuous versus intermittent cyclosporin: therapy for psoriasis. J. Dermatol. 30:2003;290-298.
13. Spencer C.M., Goa K.L., Gillis J.C. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs. 54:1997;925-975.
14. Stuetz A., Grassberger M., Meingassner J.G. Pimecrolimus (Elidel, SDZ ASM 981) - preclinical pharmacologic profile and skin selectivity. Semin. Cutan. Med. Surg. 20:2001;233-241.
15. Takatsuka H., Iwasaki T., Okamoto T., Kakishita E. Intestinal graft-versus-host disease: mechanisms and management. Drugs. 63:2003;1-15.
16. Vohr H.W. Experiences with an advanced screening procedure for the identification of chemicals with an immunotoxic potential in routine toxicology. Toxicology. 104:1995;149-158.